To provide preliminary estimates of effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treating with dipyridamole, and schizophrenia patients treated with olanzapine.
To determine if dipyridamole, a clinically available adenosine agonist, has efficacy for treating positive and negative symptoms and cognitive deficits of schizophrenia.
18 Years to 65 Years (Adult)
July 10, 2006
January 14, 2013
Maryland Psychiatric Research Center Baltimore, Maryland, United States
† Study has passed its completion date and status has not been verified in more than two years.